Supercharge Your Innovation With Domain-Expert AI Agents!

Application of crm197 in preparation of medicine for treating polycystic ovary syndrome

A 1.CRM197, polycystic ovary technology, applied in the field of biomedicine, can solve the problem of statins increasing the risk of cancer, and achieve the effects of improving ovarian polycystic appearance, reducing the number of antral follicles, and inhibiting the proliferation of granulosa cells

Active Publication Date: 2021-08-13
金华市人民医院
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] [5], Chen Hong, Ren Jingyi. There is no definite evidence that statins increase the risk of cancer [J]. Chinese Journal of Cardiovascular Diseases, 2011,39(3):196-198.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of crm197 in preparation of medicine for treating polycystic ovary syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1. Application of CRM197 in the preparation of medicines for treating polycystic ovary syndrome.

[0029] The specific implementation is as follows:

[0030] 1. Materials and methods:

[0031] 1.1. Experimental animals:

[0032] Forty-five 70-day-old healthy and clean female Spragu Dawley (SD) rats were selected from the Experimental Animal Center of Zhejiang University. The feeding temperature was 20±2°C. Rats had free access to food and water.

[0033] 1.2. Random grouping:

[0034] There were 15 rats in the normal control group, 15 rats in the model control group, and 15 rats in the CRM197 treatment group.

[0035] 1.3. Animal model preparation:

[0036] The model control group and the CRM197 treatment group established polycystic ovary syndrome (PCOS) rat models according to the Poretsky method, and subcutaneously injected human chorionic gonadotropin (HCG) 3.0 U / d twice a day, from the first day to the tenth day. The effective insulin starts from 0.5U...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of biomedicine, in particular, the invention discloses the application of RM197 in the preparation of medicine for treating polycystic ovary syndrome. The invention blocks the combination of heparin-binding epidermal growth factor and epidermal growth factor receptor through CRM197, inhibits the proliferation of granulosa cells in polycystic ovary syndrome, thereby reducing the number of antral follicles and improving the appearance of ovarian polycystic.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to an application of CRM197 in the preparation of medicines for treating polycystic ovary syndrome. Background technique [0002] Cross-reacting material 197 (CRM197) is a non-toxic mutant of diphtheria toxin, which can bind to the specific diphtheria toxin receptor (DTR) on the cell membrane, that is, the membrane of heparin-binding epidermal growth factor Binding to precursor (pro heparin-binding epidermal growth factor, PROHB-EGF). [0003] Nowadays, various studies have been conducted on the anticancer effect of CRM197. For example, the patent No. 200680022003.9 of the invention patent "Anticancer Therapeutic Agent" informed the application of CRM197 for the preparation of drugs for the treatment of diffuse peritoneal metastases of bladder cancer, colon cancer or gastric cancer and pancreatic cancer. In the non-patent literature "Research Progress of Cross Reactive Substance 197 in ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/16A61P15/00
CPCA61K38/164
Inventor 陈晓余柯达师帅邹立波郭银花俞北伟
Owner 金华市人民医院
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com